Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras association domain-containing protein 4 (RASSF4) is a member of the Ras association domain family and functions as a putative tumor suppressor. It is involved in promoting cell cycle arrest and apoptosis, particularly through mechanisms dependent on p53 and Chk2 signaling. RASSF4 is frequently silenced by epigenetic mechanisms (e.g., promoter methylation) in a variety of cancers, such as gastric cancer and multiple myeloma. Restoring RASSF4 expression reduces cell proliferation, induces apoptosis, and sensitizes tumor cells to chemotherapeutics. As a Ras effector, RASSF4 is implicated in signal transduction and scaffolding functions related to the cytoskeleton and mitotic progression
Epigenetic modulators increase RASSF4 expression (e.g., HDAC inhibitors, DNA methyltransferase inhibitors); Combination therapies involving MEK/ERK inhibitors and proteasome inhibitors exploit RASSF4 pathway activation
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras association domain-containing protein 4 (RASSF4).